Recruiting Lupus Studies in New Haven
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC)...
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis...
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack ...
Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study
The goal of this clinical trial is to test if bexagliflozin lowers the sleep apnea severity in adults who are overweight or obese with moderate to severe obstructive sleep apnea (OSA) compared with a ...
VIBRANT: VIB4920 for Active Lupus Nephritis
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in parti...
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is ha...
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus...
About Lupus Clinical Trials in New Haven
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect the joints, skin, kidneys, brain, and other organs. It is more common in women and often involves periods of flares and remission. Treatment includes antimalarials, immunosuppressants, and biologics.
There are currently 7 lupus clinical trials recruiting participants in New Haven, CT. These studies are seeking a combined 1,339 participants. Research is being sponsored by Novartis Pharmaceuticals, AstraZeneca, State University of New York - Upstate Medical University and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Lupus Clinical Trials in New Haven — FAQ
Are there lupus clinical trials in New Haven?
Yes, there are 7 lupus clinical trials currently recruiting in New Haven, CT. Browse the studies on this page to find one that fits.
How do I join a clinical trial in New Haven?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.
Are clinical trials in New Haven free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.
What lupus treatments are being tested?
The 7 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for lupus.
Data updated March 2, 2026 from ClinicalTrials.gov